AVALO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.15 USD | +4.45% |
|
+4.28% | +44.51% |
| Jun. 24 | Avalo Therapeutics Names Chief Legal Officer | MT |
| Jun. 24 | Avalo Therapeutics, Inc. Appoints Paul Varki as Chief Legal Officer | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 18,865 | 4,212 | 190.9 | 47.45 | 7.295 | 13.6 | - | - |
| Enterprise Value (EV) 1 | 18,865 | 4,212 | 190.9 | 47.45 | 7.295 | 13.6 | 13.6 | 13.6 |
| P/E ratio | -19.2 x | -3.07 x | -2.05 x | -1.14 x | -0.08 x | -14.5 x | -13.6 x | -12.8 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1,115 x | 629 x | 35.4 x | 2.63 x | 3.79 x | - | - | - |
| EV / Revenue | 1,115 x | 629 x | 35.4 x | 2.63 x | 3.79 x | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | -2,689,073 x | -1,767,381 x | - | - | - | - |
| FCF Yield | - | - | -0% | -0% | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 1,215 | 554 | 39 | 39.2 | 802 | 1,034 | - | - |
| Reference price 2 | 15,523 | 7,603 | 4,896 | 1,210 | 9.100 | 13.15 | 13.15 | 13.15 |
| Announcement Date | 3/11/20 | 3/8/21 | 3/2/22 | 3/29/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 16.92 | 6.699 | 5.398 | 18.05 | 1.924 | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -16.14 | -47.29 | -82.13 | -37.44 | -27.35 | -33 | -36 | -39 |
| Operating Margin | -95.39% | -705.99% | -1,521.56% | -207.41% | -1,421.57% | - | - | - |
| Earnings before Tax (EBT) 1 | -15.72 | -67.18 | -84.54 | -41.63 | -31.53 | -33 | -36 | -39 |
| Net income 1 | -16.07 | -63.5 | -84.38 | -41.66 | -31.54 | -33 | -36 | -39 |
| Net margin | -95.01% | -947.9% | -1,563.1% | -230.78% | -1,639.5% | - | - | - |
| EPS 2 | -806.4 | -2,477 | -2,390 | -1,063 | -114.0 | -0.9100 | -0.9700 | -1.030 |
| Free Cash Flow | - | - | -71 | -26.85 | - | - | - | - |
| FCF margin | - | - | -1,315.39% | -148.72% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/11/20 | 3/8/21 | 3/2/22 | 3/29/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.219 | 1.173 | 1.033 | 14.95 | 0.896 | 0.475 | 0.643 | 0.236 | 0.571 | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -17.96 | -20.85 | -11.83 | 4.095 | -8.855 | -9.267 | -7.15 | -3.75 | -7.658 | -32.77 | -6.7 | -12.8 | -8.8 |
| Operating Margin | -8,202.28% | -1,777.75% | -1,145.01% | 27.39% | -988.28% | -1,950.95% | -1,111.98% | -1,588.98% | -1,341.16% | - | - | - | - |
| Earnings before Tax (EBT) 1 | -19.15 | -22.04 | -12.98 | 3.197 | -9.804 | -9.947 | -8.186 | -5.22 | -8.177 | -121.3 | -6.7 | -12.8 | -8.8 |
| Net income 1 | -19.2 | -22.05 | -12.99 | 3.192 | -9.812 | -9.955 | -8.193 | -5.228 | -8.168 | -121.3 | -6.7 | -12.8 | -8.8 |
| Net margin | -8,765.3% | -1,879.88% | -1,257.21% | 21.35% | -1,095.09% | -2,095.79% | -1,274.18% | -2,215.25% | -1,430.47% | - | - | - | - |
| EPS 2 | -460.8 | -576.0 | -331.2 | 81.60 | -249.6 | -204.0 | -141.6 | -26.40 | -113.0 | -141.0 | -0.1900 | -0.3600 | -0.2500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/22 | 5/5/22 | 8/4/22 | 11/7/22 | 3/29/23 | 5/4/23 | 8/3/23 | 11/9/23 | 3/29/24 | 5/13/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | -71 | -26.8 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | 0.11 | - | - | - | - | - |
| Capex / Sales | - | - | 2.09% | - | - | - | - | - |
| Announcement Date | 3/11/20 | 3/8/21 | 3/2/22 | 3/29/23 | 3/29/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
13.15
USD
Average target price
35
USD
Spread / Average Target
+166.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.51% | 13.6M | |
| +17.09% | 44.63B | |
| +45.09% | 40.46B | |
| -9.70% | 38.07B | |
| +33.28% | 32.27B | |
| -8.98% | 27.3B | |
| +13.37% | 26.53B | |
| +44.11% | 14.06B | |
| +32.33% | 12.54B | |
| -7.26% | 11.28B |
- Stock Market
- Equities
- AVTX Stock
- Financials Avalo Therapeutics, Inc.
